Skip to Content


National Center for Advancing Translational Sciences; Notice of Meeting

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Cures Acceleration Network Review Board. The meeting will be open to the public, viewing virtually by WebEx. Individuals can register to view and access the meeting by the link below.​ncatsevents/​onstage/​g.php?​MTID=​eb948880d82d5d6f0c3d3b5ad5cd7429e.

1. Go to “Event Status” on the left hand side of page, then click “Register”. On the registration form, enter your information and then click “Submit” to complete the required registration.

2. You will receive a personalized email with the live event link.

Name of Committee: Cures Acceleration Network Review Board.

Date: December 12, 2014.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: The CAN Review Board will meet virtually to discuss updates regarding CAN programs and next steps.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Danilo A. Tagle, Ph.D., Executive Secretary, National Center for Advancing Translational, Sciences, 1 Democracy Plaza, Room 992, Bethesda, MD 20892, 301-594-8064,

This notice is being published less than 15 days prior to the meeting due to finalizing the agenda and scheduling of meeting topics.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Start Signature

Dated: November 19, 2014.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 2014-27819 Filed 11-24-14; 8:45 am]